Abarelix

CHEMBL1252 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1416.1 g/mol

LogP

3.7

Phase

4

A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.

Masse moléculaire

1416,1000 g/mol

LogP

3,70

TPSA

425,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Endometriosis Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1

Molecular Formula

C72H95ClN14O14

HBD / HBA

13 / 16

Liaisons Rotatives

38

Atomes Lourds

101

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.

Yes, Abarelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1252. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16131215. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Abarelix sur PillFYI

Structure

Données Clés

Formule: C72H95ClN14O14

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.